These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 12091648)

  • 1. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.2. Haematological complications. Leukopenia.
    EBPG Expert Group on Renal Transplantation
    Nephrol Dial Transplant; 2002; 17 Suppl 4():49. PubMed ID: 12091648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.1. Haematological complications. Anaemia.
    EBPG Expert Group on Renal Transplantation
    Nephrol Dial Transplant; 2002; 17 Suppl 4():48-9. PubMed ID: 12091647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil.
    Brum S; Nolasco F; Sousa J; Ferreira A; Possante M; Pinto JR; Barroso E; Santos JR
    Transplant Proc; 2008 Apr; 40(3):752-4. PubMed ID: 18455007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis after conversion from azathioprine to mycophenolate mofetil in a long-term renal transplant recipient.
    Mercadal L; Foltz V; Isnard-Bagnis C; Ourahma S; Deray G
    Transplant Proc; 2005 Dec; 37(10):4241-3. PubMed ID: 16387088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression.
    Bernabeu-Wittel M; Naranjo M; Cisneros JM; Cañas E; Gentil MA; Algarra G; Pereira P; González-Roncero FJ; de Alarcón A; Pachón J
    Eur J Clin Microbiol Infect Dis; 2002 Mar; 21(3):173-80. PubMed ID: 11957018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does mycophenolate mofetil increase the incidence of infections in renal transplant recipients?
    Prokopenko E; Scherbakova E; Vatazin A; Pasov S; Budnikova N; Agafonova S
    Drugs Exp Clin Res; 2005; 31(5-6):199-205. PubMed ID: 16425976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?
    Basic-Jukic N; Kes P; Bubic-Filipi LJ; Puretic Z; Brunetta B; Pasini J
    Transplant Proc; 2005 Mar; 37(2):850-1. PubMed ID: 15848553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-life-threatening leukopenia in a renal transplant recipient with acute overdose of mycophenolate mofetil.
    Wu SW; Chang HR; Lai YR; Lian JD
    Transplant Proc; 2008 Dec; 40(10):3770-1. PubMed ID: 19100486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.3. Haematological complications. Erythrocytosis.
    EBPG Expert Group on Renal Transplantation
    Nephrol Dial Transplant; 2002; 17 Suppl 4():49-50. PubMed ID: 12091649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.
    Remuzzi G; Cravedi P; Costantini M; Lesti M; Ganeva M; Gherardi G; Ene-Iordache B; Gotti E; Donati D; Salvadori M; Sandrini S; Segoloni G; Federico S; Rigotti P; Sparacino V; Ruggenenti P
    J Am Soc Nephrol; 2007 Jun; 18(6):1973-85. PubMed ID: 17460145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up.
    Ducloux D; Motte G; Billerey C; Bresson-Vautrin C; Vautrin P; Rebibou JM; Saint-Hillier Y; Chalopin JM
    Transpl Int; 2002 Sep; 15(8):387-92. PubMed ID: 12221456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil.
    Chandrakantan A; Ratanapanichkich P; Said M; Barker CV; Julian BA
    Nephrol Dial Transplant; 2005 Jun; 20(6):1214-21. PubMed ID: 15797890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
    Remuzzi G; Lesti M; Gotti E; Ganeva M; Dimitrov BD; Ene-Iordache B; Gherardi G; Donati D; Salvadori M; Sandrini S; Valente U; Segoloni G; Mourad G; Federico S; Rigotti P; Sparacino V; Bosmans JL; Perico N; Ruggenenti P
    Lancet; 2004 Aug 7-13; 364(9433):503-12. PubMed ID: 15302193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Leukopenia in kidney transplantation resulting from the interaction between mycophenolate mofetil and valganciclovir].
    Izquierdo MJ; Rodrigo E; de Cos MA; Arias M
    Nefrologia; 2007; 27(2):232-3. PubMed ID: 17564576
    [No Abstract]   [Full Text] [Related]  

  • 15. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients.
    EBPG Expert Group on Renal Transplantation
    Nephrol Dial Transplant; 2002; 17 Suppl 4():50-5. PubMed ID: 12091650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.5. Cardiovascular risks. Hyperhomocysteinaemia.
    EBPG Expert Group on Renal Transplantation
    Nephrol Dial Transplant; 2002; 17 Suppl 4():28-9. PubMed ID: 12091633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential therapies for proliferative lupus nephritis.
    Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
    N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.
    Moreso F; Serón D; Morales JM; Cruzado JM; Gil-Vernet S; Pérez JL; Fulladosa X; Andrés A; Grinyó JM
    Clin Transplant; 1998 Jun; 12(3):198-205. PubMed ID: 9642510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.6. Cardiovascular risks. Smoking.
    EBPG Expert Group on Renal Transplantation
    Nephrol Dial Transplant; 2002; 17 Suppl 4():29. PubMed ID: 12091634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.7. Cardiovascular risks. Obesity and weight gain.
    EBPG Expert Group on Renal Transplantation
    Nephrol Dial Transplant; 2002; 17 Suppl 4():29-30. PubMed ID: 12091635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.